Patents by Inventor Carmen Herrero

Carmen Herrero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220062166
    Abstract: A solution for sustained release of therapeutic, prophylactic and/or diagnostic agent in the inner ear has been developed. The formulation can be injected through a small gauge needle into the inner ear, where it gels to form a sustained release depot for controlled delivery of drug over a few days. In the preferred embodiment, the formulation includes a thermoresponsive sol-gel polymer such as POLOXAMER 407 which forms a stable hydrogel after trans-tympanic injection. As demonstrated by the examples, the hydrogel provides sustained release of an apoptosis inhibitory agent, LPT99, an anti-apoptosis agent that inhibits apoptotic protease activating factor 1 (APAF-1), as well as safety and efficacy in in vitro and in vivo models.
    Type: Application
    Filed: January 9, 2020
    Publication date: March 3, 2022
    Inventors: Carmen Herrero, Andrew Ayoob, Justin Hanes, Hugo Peris
  • Publication number: 20210293830
    Abstract: The invention relates to a method for therapy guidance, stratification and/or control in a patient with symptoms of an infectious disease, comprising a prognosis of disease progression, the method comprising: providing a sample from said patient, and determining a level of proADM or fragment(s) thereof in said sample, wherein a low risk level of proADM level or fragment(s) thereof in said sample indicates that the patient is not at risk of a disease progression to a condition that requires hospitalization, wherein said low risk level is preferably equal or below 1.2 nmol/l±20%, and/or wherein a high risk level of proADM level or fragment(s) thereof in said sample indicates that the patient is at risk of a disease progression to a condition that requires hospitalization, wherein said high risk level is preferably above 1.2 nmol/l±20%. The invention further relates to a test kit for carrying out the method.
    Type: Application
    Filed: August 8, 2019
    Publication date: September 23, 2021
    Applicants: B.R.A.H.M.S GmbH, Instituto de Investigación Biomédica de Salamanca
    Inventors: Darius Wilson, Jesús Francisco Bermejo Martin, Luis Garcia Ortiz, Carmen Herrero Rodriguez
  • Publication number: 20200214976
    Abstract: A solution for sustained release of therapeutic, prophylactic and/or diagnostic agent in the inner ear has been developed. The formulation can be injected through a small gauge needle into the inner ear, where it gels to form a sustained release depot for controlled delivery of drug over a few days. In the preferred embodiment, the formulation includes a thermoresponsive sol-gel polymer such as POLOXAMER 407 which forms a stable hydrogel after trans-tympanic injection. As demonstrated by the examples, the hydrogel provides sustained release of an apoptosis inhibitory agent, LPT99, an anti-apoptosis agent that inhibits apoptotic protease activating factor 1 (APAF-1), as well as safety and efficacy in in vitro and in vivo models.
    Type: Application
    Filed: January 9, 2019
    Publication date: July 9, 2020
    Inventors: Carmen Herrero, Andrew Ayoob, Justin Hanes, Hugo Peris
  • Publication number: 20200215194
    Abstract: A formulation for sustained release of an apoptosis inhibitor in the inner ear to protect from hearing loss, especially due to exposure to chemotherapy with drugs such as cisplatin. The formulation can be injected through a small gauge needle into the inner ear, where it gels to form a sustained release depot for controlled delivery of drug over a few days. In the preferred embodiment, the formulation includes a thermoresponsive sol-gel polymer such as POLOXAMER 407 and an apoptosis inhibitory agent, preferably an inhibitor of apoptotic protease activating factor-1 (APAF-1), in an effective amount to prevent hearing loss, for example, due to the administration of platinum-based chemotherapeutic agents. As demonstrated by the examples, the hydrogel provides sustained release of an apoptosis inhibitory agent, LPT99, an anti-apoptosis agent that inhibits apoptotic protease activating factor-1 (APAF-1), as well as safety and efficacy in in vitro and in vivo models.
    Type: Application
    Filed: January 10, 2020
    Publication date: July 9, 2020
    Inventors: Carmen Herrero, Andrew Ayoob, Justin Hanes, Hugo Peris
  • Patent number: 10561736
    Abstract: A formulation for sustained release of an apoptosis inhibitor in the inner ear to protect from hearing loss, especially due to exposure to chemotherapy with drugs such as cisplatin. The formulation can be injected through a small gauge needle into the inner ear, where it gels to form a sustained release depot for controlled delivery of drug over a few days. In the preferred embodiment, the formulation includes a thermoresponsive sol-gel polymer such as POLOXAMER 407 and an apoptosis inhibitory agent, preferably an inhibitor of apoptotic protease activating factor-1 (APAF-1), in an effective amount to prevent hearing loss, for example, due to the administration of platinum-based chemotherapeutic agents. As demonstrated by the examples, the hydrogel provides sustained release of an apoptosis inhibitory agent, LPT99, an anti-apoptosis agent that inhibits apoptotic protease activating factor-1 (APAF-1), as well as safety and efficacy in in vitro and in vivo models.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: February 18, 2020
    Assignee: Spiral Therapeutics, Inc.
    Inventors: Carmen Herrero, Andrew Ayoob, Justin Hanes, Hugo Peris
  • Patent number: 8350018
    Abstract: The present invention relates to Haemophilus parasuis polynucleotides produced by recombinant technology. It also relates to polypeptides that are expressed by said polynucleotides and also to a vaccine against H. parasuis that comprises said polypeptides. In another aspect, the invention also relates to the use of polynucleotides to determine if a strain of H. parasuis is virulent or avirulent.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: January 8, 2013
    Assignee: Fundacio Centre de Recerca en Sanitat Animal
    Inventors: Albert Bensaid, Sonia Pina Pedrero, Raquel Rivas Adan, Simone Oliveira, Enric Espuña Maso, Carmen Herrero Molina
  • Publication number: 20100285070
    Abstract: The present invention relates to Haemophilus parasuis polynucleotides produced by recombinant technology. It also relates to polypeptides that are expressed by said polynucleotides and also to a vaccine against H. parasuis that comprises said polypeptides. In another aspect, the invention also relates to the use of polynucleotides to determine if a strain of H. parasuis is virulent or avirulent.
    Type: Application
    Filed: September 15, 2006
    Publication date: November 11, 2010
    Applicant: LABORATORIOS HIPRA, S.A.
    Inventors: Albert Bensaid, Sonia Pina Pedrero, Raquel Rivas Adan, Simone Oliveira, Enric Espuña Maso, Carmen Herrero Molina